Serum Institute of India (SII), Pune, announced on 5 October 2026 that Cervavac, India's first indigenously developed quadrivalent HPV vaccine, has received World Health Organization (WHO) prequalification. It is SII's 32nd prequalification.
Prequalification places Cervavac on WHO's list of prequalified vaccines, so United Nations agencies can procure it for global immunisation programmes.
Cervavac targets HPV types 6, 11, 16 and 18 and is gender-neutral: it is indicated for girls and boys aged 9 to 26.
It was developed with the Department of Biotechnology, BIRAC, WHO's International Agency for Research on Cancer (IARC) and the Gates Foundation. India's drug regulator cleared it on 12 July 2022 and it was launched on 24 January 2023.
India's own nationwide HPV vaccination programme, launched on 28 February 2026 for 14-year-old girls, uses a different vaccine, Gardasil.
WHO assesses a vaccine's quality, safety and efficacy data and its manufacturing site. A product that passes is added to the list of prequalified vaccines, from which UN agencies such as UNICEF buy for immunisation programmes in low- and middle-income countries.
Simple Analogy: A quality stamp that lets a vaccine enter global public tenders.
| Vaccine | Maker | HPV types covered |
|---|---|---|
| Cervarix | GSK | 16, 18 (bivalent) |
| Gardasil | MSD (Merck) | 6, 11, 16, 18 (quadrivalent) |
| Gardasil 9 | MSD (Merck) | 6, 11, 16, 18, 31, 33, 45, 52, 58 (nonavalent) |
| Cecolin | Xiamen Innovax, China | 16, 18 (bivalent); prequalified October 2021 |
| Walrinvax | Zerun Bio (Walvax), China | 16, 18 (bivalent); prequalified 2024 |
| Cervavac | Serum Institute of India | 6, 11, 16, 18 (quadrivalent); announced October 2026 |
Free HPV vaccination of 14-year-old girls to prevent cervical cancer
Key: Launched by the Prime Minister at Ajmer, Rajasthan, on 28 February 2026; single dose of Gardasil; tracked on the U-WIN platform
Eliminate cervical cancer as a public health problem
Key: 90-70-90 targets for 2030: 90% of girls vaccinated by 15, 70% of women screened by 35 and again by 45, 90% of women with cervical disease treated
World's largest vaccine maker by number of doses; founded in 1966 by Cyrus Poonawalla
UN health agency; runs the prequalification programme for vaccines, medicines and diagnostics
WHO's specialised cancer research agency, set up in 1965; partner in Cervavac's development
Public sector enterprise set up by the Department of Biotechnology in 2012 to support biotech innovation
India's national drug regulator, headed by the Drugs Controller General of India, who granted Cervavac market authorisation
DCGI grants market authorisation to Cervavac
Cervavac launched in India on National Girl Child Day
Nationwide HPV vaccination programme launched at Ajmer
SII announces WHO prequalification of Cervavac
GS Paper 3 > Science and Technology > Biotechnology and indigenous technology; GS Paper 2 > Health
General Awareness > Science and Health
General Awareness > Science and Technology
Which one of the following statements is not correct?
Answer: Hepatitis B, unlike Hepatitis C, does not have a vaccine.
Human Papillomavirus; types 16 and 18 cause about 70% of cervical cancers
A vaccine that protects against four types of a pathogen
WHO's quality assessment that makes a product eligible for UN procurement
One indicated for both girls and boys